Azacitidine

Before the turn of the century, intensive chemotherapy was the only therapy that could produce clinically meaningful responses in…

81% of evaluable patients achieved an objective responseDeep responses: 64% are CR/CRi, of which 86% achieved transfusion independenceRapid and durable responses: 91% by end of cycle 2,…

New drug combinations and better supportive care have led to improved outcomes in patients with acute myeloid leukemia (AML). However,…

-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS -- Objective…

Adding an isocitrate dehydrogenase 2 (IDH2) inhibitor to azacitidine significantly improved…

Robust signals of clinical efficacy, with ORR of 83%, of which 67% are CR/CRiFive patients with responses longer than 1 yearLongest remission 858 days, still ongoingRapid onset of responses…